Anxiety and Depression in Patients with Obstructive Sleep Apnoea before and after Continuous Positive Airway Pressure: The ADIPOSA Study
Metadatos
Mostrar el registro completo del ítemAutor
Carneiro Barrera, Almudena; Amaro Gahete, Francisco José; Sáez Roca, Germán; Martín Carrasco, Carlos; Buela Casal, GualbertoEditorial
MDPI
Materia
Obstructive sleep apnoea Depressions Anxiety Positive affect Euthymia Dysthymia
Fecha
2019-12-01Referencia bibliográfica
Carneiro-Barrera, A., Amaro-Gahete, F. J., Sáez-Roca, G., Martín-Carrasco, C., R Ruiz, J., & Buela-Casal, G. (2019). Anxiety and Depression in Patients with Obstructive Sleep Apnoea before and after Continuous Positive Airway Pressure: The ADIPOSA Study. Journal of Clinical Medicine, 8(12), 2099.
Patrocinador
This research was supported by the Spanish Ministry of Education and Vocational Training, grant/award number FPU16/01093 and FPU14/04172. The study was also partially supported by the University of Granada Plan Propio de Investigación 2019-Programa Contratos-Puentes; University of Granada Plan Propio de Investigación 2016-Excellence actions: Unit of Excellence on Exercise and Health (UCEES); and the Junta de Andalucía, Consejería de Conocimiento, Investigación y Universidades (European Regional Development Funds, ref. SOMM17/6107/UGR).Resumen
The prevalence and treatment response of depression and anxiety symptoms in obstructive
sleep apnoea (OSA), although widely addressed in research and clinical settings, still remain
unclear due to overlapping symptoms. The ADIPOSA study sought to elucidate the presence of
non-overlapping symptoms of depression and anxiety in patients with moderate to severe OSA
before and after continuous positive airway pressure (CPAP) treatment. Forty-eight adults aged
18–80 (68.75% men) with moderate to severe OSA were enrolled in this twelve-week longitudinal
single-arm trial and completed a full-night ambulatory sleep diagnostic test and an assessment of
cognitive-affective depression and anxiety symptoms using the Beck-Depression Inventory-Fast Screen
(BDI-FS), the State-Trait Depression Inventory (IDER) and the State-Trait Anxiety Inventory (STAI).
We found no cognitive-affective depression or anxiety symptoms of clinical relevance at baseline.
The amelioration of depression and anxiety symptoms after CPAP use was only statistically significant
when considering anxiety-trait (p < 0.01; d = 0.296) and euthymia (p < 0.05; d = 0.402), the distinctive
component of depression. Although dysthymia or high negative affect remained unchanged, CPAP
may be effective at reducing the lack of positive affect, a well-established health-protective factor.
However, not until depression and anxiety disorders related to OSA are accurately measured in
clinical and research settings will it be possible to obtain robust conclusions on the occurrence and
amelioration of these symptoms after treatment.